Spero Therapeutics, Inc. (SPRO)
Market Cap | 164.38M |
Revenue (ttm) | 44.58M |
Net Income (ttm) | -69.76M |
Shares Out | 55.91M |
EPS (ttm) | -1.28 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,848,456 |
Open | 2.950 |
Previous Close | 2.900 |
Day's Range | 2.860 - 2.980 |
52-Week Range | 0.505 - 3.060 |
Beta | 1.31 |
Analysts | Buy |
Price Target | 5.00 (+70.07%) |
Earnings Date | Aug 4, 2025 |
About SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous my... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SPRO stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 70.07% from the latest price.
News

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results
Based on the positive results of the registrational Phase 3 PIVOT-PO study, Tebipenem is expected to be approved under the SPA in mid-2026. Spero will not bear any costs or risks since GSK, as a licen...

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for...

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually ...

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare ...

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare...

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for ra...

Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Shai Biran - Senior Director Investor Relations Esther Rajavelu - Interim Chief ...

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rar...

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025
CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatm...

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical du...

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice from...

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (G...

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) Phase 1 study showed significant...

Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2024 Earnings Conference Call August 5, 2024 4:30 AM ET Company Participants Shai Biran - Senior Director Investor Relations Sath Shukla - Chief Executive Of...

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
CAMBRIDGE, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatme...

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatme...

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatme...

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatmen...

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatmen...

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatmen...

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatmen...

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excelle...